These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 2462973)

  • 21. [IgM antibodies against hepatitis B core antigens, anti-HBc-IgM. Their diagnostic significance].
    Esteban R; Guardia J; Buti M; Esteban JI; Rodrigo MJ; Jardí R; Hernández JM; Bacardí R
    Med Clin (Barc); 1984 Oct; 83(11):437-9. PubMed ID: 6503413
    [No Abstract]   [Full Text] [Related]  

  • 22. Do we have to rethink serologic markers used to diagnose hepatitis B infection?
    Roeckel IE
    Ann Clin Lab Sci; 1989; 19(6):397-400. PubMed ID: 2604376
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Clinical significance of anti-HBc and IgM.anti-HBc].
    Chen BJ
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 1988 Apr; 10(2):104-9. PubMed ID: 2970316
    [No Abstract]   [Full Text] [Related]  

  • 24. A revised method for estimating hepatitis B virus transfusion residual risk based on antibody to hepatitis B core antigen incident cases.
    Laperche S; Maniez M; Barlet V; El Ghouzzi MH; Le Vacon F; Levayer T; Lunel F; Morel P; Mouillot L; Piquet Y; Pillonel J;
    Transfusion; 2008 Nov; 48(11):2308-14. PubMed ID: 18673347
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Non-B post-transfusion hepatitis associated with hepatitis B core antibodies in donor blood.
    Vyas GN; Perkins HA
    N Engl J Med; 1982 Mar; 306(12):749-50. PubMed ID: 6801510
    [No Abstract]   [Full Text] [Related]  

  • 26. [Concentration test for determination of low-level HBsAg in donors with anti-HBc].
    Maschio C; Varrassi S; Barnabei R; Rughetti A; Fonzi D; Capulli M; Genise S
    Riv Emoter Immunoematol; 1985; 32(1):69-73. PubMed ID: 4081534
    [No Abstract]   [Full Text] [Related]  

  • 27. Lack of correlation between HBsAg and HBV DNA levels in blood donors who test positive for HBsAg and anti-HBc: implications for future HBV screening policy.
    Kuhns MC; Kleinman SH; McNamara AL; Rawal B; Glynn S; Busch MP;
    Transfusion; 2004 Sep; 44(9):1332-9. PubMed ID: 15318857
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [A retrospective study of HBsAG carriers in the blood bank of Navarra].
    Medarde A; del Hierro J; Aramburu E; Esquíroz P; Martínez JL
    Rev Med Univ Navarra; 1988; 32(4):209-16. PubMed ID: 3155332
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Anti-hepatitis B core immunoglobulin M in the serologic evaluation of hepatitis B virus infection and simultaneous infection with type B, delta agent, and non-A, non-B viruses.
    Perrillo RP; Chau KH; Overby LR; Decker RH
    Gastroenterology; 1983 Jul; 85(1):163-7. PubMed ID: 6406288
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Hepatitis B vaccination and anti-HBc-positive livers in children.
    Lacaille F
    Hepatology; 2003 Nov; 38(5):1311; author reply 1312. PubMed ID: 14578873
    [No Abstract]   [Full Text] [Related]  

  • 31. Missed opportunities: ALT and anti-HBc as surrogate tests for hepatitis.
    Bettigole R; Shastri KA
    J Med; 1997; 28(5-6):363-9. PubMed ID: 9604794
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Hepatitis B virus DNA-positive, hepatitis B surface antigen-negative blood donations intercepted by anti-hepatitis B core antigen testing: the Canadian Blood Services experience.
    O'Brien SF; Fearon MA; Yi QL; Fan W; Scalia V; Muntz IR; Vamvakas EC
    Transfusion; 2007 Oct; 47(10):1809-15. PubMed ID: 17880605
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Strategies for the prevention of post-transfusion hepatitis.
    Mintz PD
    Ann Clin Lab Sci; 1984; 14(3):198-207. PubMed ID: 6428295
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A multiple centre clinical study of third-generation enzyme immunoassays for hepatitis B surface antigen and hepatitis B core IgM class antibody.
    Jakob R
    Eur J Clin Chem Clin Biochem; 1993 Apr; 31(4):259-66. PubMed ID: 8318575
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Occult hepatitis B virus infection among anti-HBc positive blood donors: Necessitates substitution of screening by HBV NAT.
    Panhotra BR; Bahrani A; Joshi CS; ul Hassan Z
    J Infect; 2005 Oct; 51(3):263. PubMed ID: 16125778
    [No Abstract]   [Full Text] [Related]  

  • 36. Prevalence of some markers of the hepatitis B virus in a blood donor population.
    Legnani F; Azzario F; Ghessi A
    Boll Ist Sieroter Milan; 1982; 61(6):454-9. PubMed ID: 6927223
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Limitations of solid-phase radioimmunoassay for hb ag in reducing frequency of post-transfusion hepatitis.
    Hollinger FB; Aach RD; Gitnick GL; Roche JK; Melnick JL
    N Engl J Med; 1973 Aug; 289(8):385-91. PubMed ID: 4719826
    [No Abstract]   [Full Text] [Related]  

  • 38. Anti-HBc testing is reliable for blood donor screening.
    Smilovici W; Ducos J; Mariniere A
    Lancet; 1984 May; 1(8384):1024. PubMed ID: 6143954
    [No Abstract]   [Full Text] [Related]  

  • 39. Anti-HBc in blood donors.
    Moore C; Barbara J; Hewitt PE
    Vox Sang; 1998; 74(3):209. PubMed ID: 9595652
    [No Abstract]   [Full Text] [Related]  

  • 40. Evaluation of routine anti-HBc screening of volunteer blood donors: a questionable surrogate test for non-A, non-B hepatitis.
    Hanson MR; Polesky HF
    Transfusion; 1987; 27(1):107-8. PubMed ID: 3101245
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.